Nicole Murphy - 06 Feb 2025 Form 4 Insider Report for BIOGEN INC. (BIIB)

Role
Head of Pharm Ops and Tech
Signature
/s/ Samuel Ntonme, attorney-in-fact for Nicole Murphy
Issuer symbol
BIIB
Transactions as of
06 Feb 2025
Net transactions value
-$172,871
Form type
4
Filing time
10 Feb 2025, 18:47:07 UTC
Previous filing
03 Apr 2024
Next filing
12 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIIB Common Stock Options Exercise $0 +2,102 +22% $0.000000 11,736 07 Feb 2025 Direct
transaction BIIB Common Stock Tax liability $87,637 -620 -5.3% $141.35 11,116 07 Feb 2025 Direct
transaction BIIB Common Stock Options Exercise $0 +1,940 +17% $0.000000 13,056 07 Feb 2025 Direct
transaction BIIB Common Stock Tax liability $85,234 -603 -4.6% $141.35 12,453 07 Feb 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIIB Restricted Stock Unit Award $0 +14,050 $0.000000 14,050 06 Feb 2025 Common Stock 14,050 $0.000000 Direct F1
transaction BIIB Restricted Stock Unit Options Exercise $0 -2,102 -50% $0.000000 2,102 07 Feb 2025 Common Stock 2,102 $0.000000 Direct F2
transaction BIIB Restricted Stock Unit Options Exercise $0 -1,940 -33% $0.000000 3,880 07 Feb 2025 Common Stock 1,940 $0.000000 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025.
F2 The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/8/2023.
F3 The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024.